Alvotech
ALVO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $157.4M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVOW
Q1 2025 vs. Q4 2024
How the institutions holding Alvotech changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 45 | 51 | +6 |
| Shares | 15.4M | 16.7M | +1.28M (+8.3%) |
| Value | $199.6M | $159.2M | −$40.4M (−20.2%) |
New holders (7)
Institutions that held Alvotech at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Price T Rowe Associates Inc | 1,401,421 | $13.6M | 0.00% |
| SIH Partners, LLLP | 19,000 | $183.7K | 0.02% |
| Citigroup Inc | 4,387 | $42.4K | 0.00% |
| Capital Analysts, LLC | 1,791 | $17.0K | 0.00% |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 1,027 | $9.93K | 0.00% |
| Caitong International Asset Management Co., Ltd | 205 | $1.98K | 0.00% |
| Coldstream Capital Management Inc | 56 | $542 | 0.00% |
Sold out (1)
Institutions that held Alvotech at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| ADAR1 Capital Management, LLC | 20,600 | $272.5K |